Introduction {#S0001}
============

Immature dendritic cells (iDCs) play a crucial role in the surveillance of peripheral sites by migrating through all of the tissues and actively taking up foreign antigen \[[@CIT0001]\]. They present antigens on major histocompatibility complex (MHC) class I and II molecules to T cells. In addition, they are equipped with a range of pathogen sensing molecules such as toll-like receptors (TLRs), nucleotide-binding oligomerisation domain proteins (NOD), and C-type lectins that allow them to detect pathogen products and sense inflammation \[[@CIT0002]\]. The secretion of immunoregulatory cytokines such as interleukin (IL)-12 and type I interferon (IFN) are considered to be an early immune response critical for the polarisation of CD14^+^

T lymphocyte response towards a T helper pattern, a key process for the clearance of intracellular pathogens \[[@CIT0003]\]. Moreover, dendritic cells (DCs) play a major part in transplant engraftment and rejection and in graft-versus-host disease (GvHD). Preferentially tolerogenic or immunogenic DC subtypes offer targets for immunotherapy, to optimise transplant success rates and prolong disease-free and overall survival \[[@CIT0004]\]. Advances in the extraction and *in vitro* culture of DCs have been a major driving force behind the increased interest in these cells and have facilitated the inclusion of these powerful adjuvants in therapeutic trials. Refined laboratory protocols are available for either the generation of DC from a number of readily available sources or for the direct isolation of DC from mixed cell populations \[[@CIT0005]\]. Cells that have been found to yield DC, after culture in lineage-restricting cocktails of cytokines, include CD34^+^ stem cells and CD14^+^ mono-cytes. CD14^+^ monocytes are perhaps the most readily available precursors used to generate human DC, because they constitute 7-8% of human peripheral blood mononuclear cells (PBMCs) \[[@CIT0006]\].

Material and methods {#S0002}
====================

Subjects {#S20003}
--------

Peripheral blood from fifty healthy voluntary blood donors was collected from the central blood bank at Ain Shams University Hospital. All of the donors were aged between twenty and forty years, of both sexes, and were found healthy in an orienting physical examination and all blood products were negative for common blood-borne pathogens, as detected by standard blood bank assays.

In the current study, 50 samples were cultured, but because of problems encountered during culture, only 35 samples were analysed. The 35 samples were subdivided into two groups: Group 1 included 20 samples in which DCs were derived from MACS monocytes. Group 2 included 15 samples in which DCs were derived from monocytes separated by adherence.

Twenty to fifty millilitres of citrate acid dextrose or heparinised anticoagulated fresh blood were aseptically collected in sterile 50-ml polypropylene centrifuge tubes. Samples were handled maximally within eight hours, and during this time period they were kept at room temperature.

The study was approved by the ethical committees of the National Research Centre, Dokki, Giza and Ain Shams University Hospital.

Methods {#S20004}
-------

Cell culture is filled with variables that can make it difficult to determine the cause of problems. Narrowing a problem down to the one material or one critical procedure can be a daunting task. However, problems can usually be identified by carefully examining the symptoms and meticulously retracing each step in the culture process. Among the problems encountered were cell death in the culture by day 2 and contamination.

Steps for generation of immature dendritic cells {#S20005}
------------------------------------------------

### Isolation of peripheral blood mononuclear cells

Under complete aseptic conditions (laminar flow work area), the blood was diluted 1: 1 with phosphate buffered saline (PBS) (Lonza, Walkersville, USA) without Ca^2+^ and Mg^2+^ (used in all following experiments). Peripheral blood mononuclear cells were isolated from buffy coats by Ficoll-Hypaque (Lonza) density-gradient centrifugation. The separated cells were washed twice in MACS buffer (Miltenyi Biotech, Germany). Then, cell pellets were suspended in 1 ml MACS buffer then counted and tested for viability.

### Monocyte isolation from human peripheral blood

**Monocyte purification by positive selection using CD14 microbeads**Cell pellets were resuspended in a final volume of 80 μl Magnetic Activated Cell Sorted (MACS) buffer and labelled with 20 μl of microbeads with FITC (fluorescein isothiocyanate) conjugated mouse anti-human CD14 antibodies (Miltenyi Biotech).The cells were mixed well and incubated at 4°C for 15 minutes in the dark. After incubation, the cells were washed thrice with 500 μl of MACS buffer by spinning at 300 × g for 10 minutes. The cells were resuspended in 1 ml of buffer and used for magnetic sorting. The column was washed with 500 μl of MACS buffer.The magnetically labelled cells were passed through the column. The cells with magnetic microbeads were retained within the column and those that are unlabelled eluted out. The eluted fraction was collected as negative fraction. The column was washed thrice with 500 μl of MACS buffer. Then the column was removed from the magnetic field.The retained cells in the column were firmly flushed out by applying pressure on the matrix of the column by a plunger supplied with the kit. These were the positive fractions, which were washed twice with MACS buffer by spinning at 300 × g for 5 minutes and resuspended in 1 ml of MACS buffer. Then the cells were tested for viability and counted.**Monocyte purification by adherence separation**Peripheral blood mononuclear cells were allowed to adhere to a six-well tissue culture plate (3 ml/well, Costar Corp., Cambridge, MA, USA) at a density of 2 × 10^6^ cells/ ml in complete serum-free medium, which consisted of: 49.5 ml of RPMI with L-glutamine 1640 (Lonza), 250 μl amphotericin-B (0.5%) (Biowest, Nuaillé, France), and 250 μl penicillin/streptomycin (0.5%) (Biowest), for three days at 37°C and 5% CO~2~ in a fully humidified incubator. After that, non adherent cells were removed by aspiration and the flask was washed extensively twice with warm media, and the remaining adherent cells (monocytes) were removed by gentle scraping using a sterile cell scraper, and the flask was shaken then washed to help the complete detachment of the cells. Inverted microscopic examination of adherent monocytes showed small clusters of round cells with some cytoplasmic processes occasionally extending from them.Cells were centrifuged at 1200 rpm for 10 minutes and resuspended in 1 ml of MACS buffer, and then they were counted and tested for viability.

Cell culture {#S20008}
------------

Monocyte-derived DCs (MoDCs) were generated by culturing monocytes in six-well tissue culture plates (3 ml/ well) with 50 ng/ml GM-CSF and 20 ng/ml IL-4 (R&D systems, Minneapolis, USA), for seven days at 0.5 × 10^6^ cells/ml in RPMI 1640, supplemented with 2 mM L-glutamine, 15% foetal calf serum (FCS) (Biowest) together with 10 μg/ml penicillin/streptomycin, 1 μg/ml amphotericin B, 0.1 mM non essentials amino acids, 1 mM sodium pyruvate, and 50 μM 2-mercaptoethanol at 37°C in 5% CO~2~ humidified air.

Every 2-3 days, the medium was examined with an unaided eye to look for signs of microbial contamination (turbid culture media, change in the colour of the media, change in the growth rates, abnormally high pH and poor attachment). Then they were examined by the inverted phase contrast microscope (100 to 200×) for assessment of the cell condition (viable cells were round, bright and refractile) and morphology. Vacuolisation and cell lysis are signs of microbial contamination.

Additionally, every 2-3 days, the cultures were fed with fresh medium and cytokines to keep the cells healthy and actively growing, and cell viability assay was done as we changed the medium.

Monocytes cultured in the presence of GM-CSF and IL-4 acquired characteristic colony morphology. They were found to have confluent appearance, which was the result of both an increase in cell size and *de novo* proliferation, as evidenced by an increase in cell number.

Non-adherent cells, thereafter called monocyte-derived DCs, were harvested at day 7, and were then tested for viability.

Cell viability assay {#S20009}
--------------------

Trypan blue dye exclusion test was done by the method of Rosenberg *et al*. \[[@CIT0007]\]. The test is based on microscopic examination of trypan blue staining: viable cells are unstained, and dead cells contain the dye. Trypan blue solution and cell suspension were mixed in the ratio of 1: 1. Then the cells were observed under microscope and counted. The percentage of viable cells was calculated as the number of viable cells divided by the total number of cells (viable + dead cells) × 100.

Flow cytometry {#S20010}
--------------

Cell populations from each respective sample were washed with PBS and centrifuged at 1500 g (3200 rpm) for 3 minutes. After removing all but 1 ml of the supernatant, cells were resuspended. 100 μl cell suspensions were added to fluorochrome-conjugated reagents: FITC-anti-CD14, PE-anti-CD11c, PE-anti-CD1a, PE-Cy5-anti HLA-DR, and PE-anti-CD83 (Beckman Coulter, Marseille, France). Then the cells were incubated in the dark for 15 minutes after light vortexing. Stained cells were analysed by flow cytometry. Data acquisition and analysis were performed on an EPICS XL flow cytometer (Coulter Electronics, Florida, USA) using SYSTEM II version 3 software with a standard three-colour filter configuration. Cells were initially gated out on the basis of forward scatter (size) and side scatter (complexity). The initially gated cells were further analysed for CD14 and CD1a, HLA-DR, CD11c, and CD83expression.

Statistical analysis {#S20011}
--------------------

Statistical analysis was performed using IBM SPSS statistics (V. 21.0, IBM Corp., USA, 2012). Data were expressed as mean ± SD for quantitative parametric measures in addition to median percentiles for quantitative non-parametric measures and both number and percentage for categorised data. The Mann-Whitney test was used for comparison between two independent groups for non-parametric data. The independent t-test was used for comparison between two independent groups for parametric data. A *p* value \< 0.05 indicated statistical significance while *p* \< 0.01 and 0.001 indicated high statistical significance.

Results {#S0012}
=======

The mononuclear cells obtained from the fresh blood samples were tested for cell count and viability, where the cell count ranged from 1.5 to 5.0 × 10^7^ cells/ml according to the blood volume used, and the viability was 95-98%.

Monocytes separated by adherence {#S20013}
--------------------------------

The cell count ranged from 5 to 15 × 10^5^ cells/ml, while the viability ranged between 70% and 75%. Cells were also examined using Leishman stain, which clearly identified these cells as monocytes ([Fig. 1](#F0001){ref-type="fig"}).

![Morphology of purified monocytes stained by Leishman stain](CEJI-40-50828-g001){#F0001}

Magnetic activated cell sorted separated monocytes {#S20014}
--------------------------------------------------

The cell count ranged between 4 and 9 × 10^6^ cells/ml, while the viability ranged between 90% and 95%.

Living cells decreased gradually during the time course of culture as seen by the inverted microscope. On day 7, the non-adherent cells in the differentiation culture were harvested and stained with surface markers of iDCs for flow cytometry analysis. Viability was assessed and it was found that the median (IQR) percentage of MACS-DCs viability was significantly higher than that of DCs derived from monocytes separated by adherence (median 50 and interquartile range 45-50 vs. 25 and 10-30, respectively; *p* \< 0.001) ([Fig. 2](#F0002){ref-type="fig"}).

![Comparison between MACS-DCs and Flask-DCs as regards viability](CEJI-40-50828-g002){#F0002}

Immunophenotypical analysis of iDCs revealed that the median interquartile percentages of MACS-DCs expressing CD14^--^ was significantly higher compared to the DCs derived from monocytes separated by adherence (median 80.2 and interquartile range 77.7-80.7 vs. 40.2 and 30.4-40.6, respectively; *p* \< 0.001). However, MACS-DCs expressed the same levels of CD11c^+^, CD1a^+^, and HLA-DR^+^ as well as CD83^+^ compared to the DCs derived from monocytes separated by adherence with *p* value \> 0.05 ([Table 1](#T0001){ref-type="table"}).

###### 

Phenotypic comparison MACS-DCs and DCs derived from monocytes separated by adherence

                                          Immature dendritic cells derived from MACS separated monocytes (no of samples = 20)   Immature dendritic cells derived from monocytes separated by adherence (no of samples = 15)   t˙/z\*         *p* value
  --------------------------------------- ------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------- -------------- ------------
  CD14^--^ cells                          80.2 (77.7-80.7)                                                                      40.2 (30.4-40.6)                                                                              --4.402\*      0.000 (HS)
  CD14^--^/CD11c^+^ cells                 8.5 (8.1-9.5)                                                                         8.3 (8.1-9.6)                                                                                 --0.243\*      0.808 (NS)
  CD14^--^/HLA-DR^+^ cells                3.5 (3.2-4.2)                                                                         3.8 (3.4-7.4)                                                                                 --0.869\*      0.385 (NS)
  CD14^--^/CD11c^+^/HLA ^--^DR^+^ cells   86.74 ±2.41                                                                           87.53 ±1.83                                                                                   --0.910**˙**   0.371 (NS)
  CD14^--^/CD1a^+^ cells                  3.83 ±1.34                                                                            3.42 ±1.04                                                                                    --0.033**˙**   0.956 (NS)
  CD14^--^/HLA^--^DR^+^/CD83^+^           3.19 ±0.58                                                                            3.20 ±0.64                                                                                    --0.043**˙**   0.966 (NS)

t˙ -- data were presented as mean ± SD and compared together using independent t-test; z\* -- data were presented as median and IQR and compared together using Mann-Whitney test; HS -- highly significant; NS -- non significant

[Figure 3](#F0003){ref-type="fig"} shows an example of the flow cytometry charts performed in our study for analysis of immature DCs phenotype after culture of MACS separated mono-cytes.

![Phenotype of DC generated after culture of MACS separated monocytes. Dead cells were excluded by gating on forward and side scatter properties, and the remaining viable cells were analysed. Representative dot plots of FCM and the gating strategy used: **A)** shows forward and side scatters to gate monocytes; **B)** shows CD14^--^ cells were acquired after gating the monocytes population by forward and side scattered properties; **C)** gating approach for discrimination of CD14^--^ CD11c^+^ HLA-DR^+^ populations; **D)** gating approach for discrimination of CD14^--^ HLA-DR^+^ CD83^--^ populations](CEJI-40-50828-g003){#F0003}

Discussion {#S0015}
==========

Researches hold great promise for DCs in the development of cancer immunotherapies as well as the treatment of autoimmune diseases. Dendritic cells also play an essential role in the setting of HIV infection and the pathogenesis of several other viruses, and thus can be used as a therapeutic target. Therefore, a requirement for the development of a standardised DC generation protocols needed to provide 'reference dendritic cells' to which other dendritic cells could be compared \[[@CIT0008]\].

Currently, there are two known major subsets of DCs in humans: Lymphoid DCs derived from plasmacytoid cells in blood, and myeloid DCs that arise from the my-eloid precursor; and peripheral blood monocytes or CD34 progenitors from bone marrow. The most commonly used cell type for DC generation are peripheral blood monocytes, as the generation of CD34^+^ precursor-derived DCs requires a more substantial cocktail of cytokines, in addition to the need for extensive purification of CD34 precursor cells from leukapheresis products \[[@CIT0009]\].

This is a preliminary study to establish a protocol for obtaining iDCs from peripheral blood monocytes in our laboratory.

There are multiple methods for obtaining monocytes as abundant and simply available cells in the peripheral blood. Some of these methods include plastic/glass adherence \[[@CIT0010]\], density gradient centrifugation \[[@CIT0011]\], and specific marker-based separations such as magnetic activated cell sorting, fluorescent activated cell sorting (FACS), and bipolar tetrameric antibody (Ab)-based separation \[[@CIT0012]\]. In this study, the effects of two monocyte separation methods including MACS and cell culture flask adherence methods were compared regarding the production of DCs by several phenotypic analyses. The MACS method is based upon a monocyte-specific marker, i.e. CD14, and the cell culture flask adherence method is based upon the fact that β2 integrin expressing cells can adhere to plastic or glass \[[@CIT0013]\]. In this study, the expression of CD11c, HLA-DR, CD83, and CD1a was the same regardless of the method used to isolate the original CD14^+^ cells. However, the MACS method is rapid and produces cell populations with high viability and purity, compared to monocytes separated by adherence method. These results were in partial agreement with Delirezh and Shojaeefar \[[@CIT0013]\]. They demonstrated that the viability of MACS-DCs was slightly higher than Flask-DCs and that they express higher levels of CD14^--^ in comparison to Flask-DCs. In contrast to our results, they revealed that MACS-DCs expressed higher levels of CD83^+^ and HLA-DR^+^ compared to the Flask-DCs. Induction of T cell proliferative responses was higher in Flask-DCs and they also elicited higher levels of IL-12: IL-10 and IFN-γ: IL-4 ratios in cytokine generation assays. However, they recommended further work to study the impact of both methods on the subsequent function of DC. Therefore, we started to study the kinetics of monocyte differentiation into DCs to determine the optimum time at which we can obtain immature DCs with the best viability, this was accomplished through staining the cells with surface markers of immature DCs: CD14, CD11c, CD1a, HLA-DR, and CD83 monoclonal antibodies for flow cytometry analysis every two days.

Within the human blood, DCs are lineage (CD3, CD14, CD19, CD56) negative and HLA-DR positive \[[@CIT0014]\]. The CD1a molecule is considered a specific marker of immature DCs \[[@CIT0015]\]. In this study, however, CD 1a was only expressed on a small percentage of iDCs (0.2%) generated from peripheral blood monocytes. On the other hand, 87.5% were CD14^--^ HLA-DR^+^ CD11c^+^. This was in agreement with Osada *et al*. \[[@CIT0014]\], who stated that MoDCs are CD11c^+^ CD14^--^ HLA-DR^+^ with a fraction being CD1a^+^, while DCs generated from CD34^+^ haematopoietic stem cells (HSCs) are also CD11c^+^ CD14^--^ HLA-DR^+^ but with a greater percentage of them being CD1a^+^.The results of this study were also in agreement with Osugi *et al*. \[[@CIT0016]\], who found that the Mo-DCs derived after seven days in vitro culture lacked CD1a antigen, as reported in 21 out of 24 experiments, but expressed HLA-DR. However, in a study done by Angelini *et al*. \[[@CIT0017]\] myeloid DCs were defined as CD14^--^, CD1a^+^, and CD11c^+^. Colić *et al*. \[[@CIT0018]\] defined iDCs by the expression of CD1a, CD80, CD86, and HLA-DR with down-regulation of CDI4 and the absence of CD83. Elkord *et al*. \[[@CIT0019]\] demonstrated that iDCs are phenotypically different from their monocyte precursors. They express lower levels of CD14 and higher levels of HLA-DR and CD86. Immature dendritic cells express CD1a and low levels of CD80, but do not express CD83. Kolli *et al*. \[[@CIT0020]\] also confirmed DC phenotype by flow cytometry for other surface markers, including CD11b, CD11c, MHC class II, CD80, and CD86. Dzionek *et al*. \[[@CIT0021]\] found that BDCA-2 and BDCA-4 are expressed on CD11c -- CD123-bright plasmacytoid dendritic cells, which are immature dendritic cells. Others identified dendritic cells as being CD45^+^CD3-CD14^--^ 16- 19- 20- 56- HLA-DR bright \[[@CIT0022]\]. In a study done by Tkachenko *et al*. \[[@CIT0015]\] the following culture media were used: RPMI 1640 supplemented with 2% human serum albumin; RPMI 1640 supplemented with 2% TCH serum replacement; X-VIVO 15; and Panserin 501. Flow cytometry analysis revealed that in all media iDC cells were CD45^+^ CD83^+^ and lost CD14. They used the following panel to identify iDCs: CD14-CD1a^+^, CD45^+^, CD80^+^, CD86^+^, and CD83^+^.

In the present study, iDCs were generated by culturing monocytes with 10 ng/ml IL-4 and 50 ng/ml GM-CSF \[[@CIT0001]\]. Other researchers used different concentrations of growth factors and yet their attempts were successful as regards DC yield. These concentrations were as follows: 100 ng/ ml GM-CSF and 20 ng/ml IL-4 \[[@CIT0023]\], 10 ng/ml GM-CSF and 20 ng/ml IL-4 \[[@CIT0024]\], 100 ng/ml GM-CSF and 20 ng/ml IL-4 Kolli \[[@CIT0020]\] and 50 ng/ml GM-CSF and 50 ng/ml IL-4 Stocki \[[@CIT0025]\].

As regards antibiotics, some researchers recommended not using antibiotics in the culture medium because this may lead to the appearance of antibiotic-resistant strains \[[@CIT0001]\]. Consequently, at the start of the study, antibiotics were not added to the culture medium, but contamination occurred. So penicillin/ streptomycin as well as Amphotericin B were added to the culture media in this study. Also, copper sulphate was used, as records demonstrate that copper can inhibit the growth of many different microorganisms, by using it in the CO~2~ incubator \[[@CIT0026]\].

The results of the study revealed that the anticoagulant used for blood collection (citrate or heparin) did not affect monocyte differentiation into DCs. Aiba *et al*. \[[@CIT0027]\] and Tkachenko *et al*. \[[@CIT0015]\] used heparin, Facci *et al*. \[[@CIT0028]\] used EDTA while Giacomini *et al*. \[[@CIT0001]\] used citrate. Their studies showed similar results as regards DC yields.

Conclusions {#S0016}
===========

In conclusion, the present study is a preliminary trial for the generation of immature MoDCs *in vitro*. Positively selected blood monocytes and those selected by adherence gave the same results as regards cell surface marker expression although the viability and purity of MACS-separated mono-cytes were better. In addition, the use of a panel of surface markers for identification of *in vitro* generated dendritic cells is highly recommended. Further studies are recommended for the study of kinetics of monocyte differentiation into DCs. Also, further maturation of iDCs generated from peripheral blood monocytes using tumor necrosis factor α (TNF-α), LPS, or CD40L is recommended for further use of mature DCs in DC vaccines for cancer therapy as well as for the treatment of some infectious diseases. In the current study, unfortunately, we did not compare both methods on the blood from one donor. This point should be considered in future studies to make the comparison more accurate.
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